{
    "clinical_study": {
        "@rank": "38501", 
        "arm_group": [
            {
                "arm_group_label": "MLN9708 Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.\nPatients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle"
            }, 
            {
                "arm_group_label": "MLN9708 Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.\nPatients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle"
            }, 
            {
                "arm_group_label": "MLN9708 Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral dose of MLN9708 capsule on Day 1.\nPatients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive MLN9708 on Days 1, 8, and 15 of a 28-day cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, 2-part, pharmacokinetic study in patients with advanced solid tumors or\n      hematologic malignancies and varying degrees of liver dysfunction (normal function, moderate\n      or severe hepatic impairment) as defined by the National Cancer Institute (NCI) Organ\n      Dysfunction Working Group."
        }, 
        "brief_title": "Pharmacokinetic Study of Oral MLN9708 in Cancer Patients With Liver Dysfunction", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumors", 
            "Hematologic Malignancies"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Liver Diseases", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Patients must have a diagnosis of an advanced malignant solid tumor or hematologic\n             malignancy for which standard, curative, or life-prolonging treatment does not exist\n             or is no longer effective\n\n          -  Total bilirubin and aspartate aminotransferase (AST) levels consistent with normal\n             liver function (total bilirubin and AST \u2264 the upper limit of normal), moderate\n             hepatic impairment (total bilirubin > 1.5 to 3x the upper limit of normal with any\n             AST level) or severe hepatic impairment (total bilirubin > 3x the upper limit of\n             normal with any AST level)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n\n          -  Female patients who are postmenopausal for at least 1 year OR are surgically sterile\n             OR if of childbearing potential, agree to practice 2 effective methods of\n             contraception at the same time during the entire study through 90 days after the last\n             dose of study drug OR agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception during the entire\n             study and through 90 days after the last dose of study drug OR agree to practice true\n             abstinence\n\n          -  Voluntary written consent\n\n          -  Suitable venous access for the conduct of blood sampling\n\n          -  Appropriate clinical laboratory values as specified in the protocol\n\n        Exclusion Criteria:\n\n          -  Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate\n             inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba\n             or St. John's wort within 14 days before the first dose of study drug\n\n          -  Use of any nicotine-containing products within 14 days before the first dose of study\n             drug\n\n          -  Central Nervous System Involvement or Symptomatic brain metastasis.  Patients with\n             brain metastases: must have stable neurologic status following local therapy (surgery\n             or radiation) for at least 2 weeks after completion of the definitive therapy; and\n             must be without neurologic dysfunction that would confound the evaluation of\n             neurologic and other AEs\n\n          -  Female patients who are lactating or breastfeeding or have a positive serum pregnancy\n             test\n\n          -  Serious medical or psychiatric illness that could interfere with participation in the\n             study\n\n          -  Treatment with any investigational products or radiotherapy within 21 days before the\n             first dose of study drug\n\n          -  Systemic anticancer therapy within 14 days before the first dose of study drug\n\n          -  Exposure to nitrosoureas or mitomycin C within 6 weeks before the first dose of study\n             drug\n\n          -  Treatment with therapeutic monoclonal antibodies or antibody-drug conjugates within\n             60 days before the first dose of study drug\n\n          -  Radiotherapy or major surgery within the 14 days preceding the first dose of study\n             drug\n\n          -  Infection requiring systemic intravenous antibiotic therapy or other serious\n             infection within 14 days before the first dose of study drug\n\n          -  Life-threatening illness unrelated to cancer\n\n          -  Severe CNS, pulmonary, or renal disease not related to the patient's cancer\n\n          -  Known human immunodeficiency virus (HIV) positive\n\n          -  Any cardiovascular condition specified in the study protocol\n\n          -  QTc > 500 milliseconds (msec) on a 12-lead ECG obtained during the Screening period\n\n          -  Known GI disease or GI procedure that could interfere with the oral absorption or\n             tolerance of MLN9708\n\n          -  Known allergy to the study medication, its analogues, or excipients in the\n             formulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912222", 
            "org_study_id": "C16018"
        }, 
        "intervention": {
            "arm_group_label": [
                "MLN9708 Arm 1", 
                "MLN9708 Arm 2", 
                "MLN9708 Arm 3"
            ], 
            "intervention_name": "MLN9708", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fairway", 
                        "country": "United States", 
                        "state": "Kansas"
                    }, 
                    "name": "Kansas University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robin Norris"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "University Hospitals of Cleveland"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Nemunaitis"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Mary Crowley Cancer Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gerald Falchook"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Pharmacokinetic Study of Oral MLN9708 in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "MLN9708 in plasma", 
                "measure": "Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 15 of Part A"
            }, 
            {
                "description": "MLN9708 in Plasma", 
                "measure": "Maximum (peak) concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 15 of Part A"
            }, 
            {
                "description": "Safety and tolerability of MLN9708.", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose of study drug through 30 days after the last dose of study drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912222"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}